Your browser doesn't support javascript.
Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience.
Alwahdy, Ahmad Sulaiman; Margaretha, Ika Yulieta; Pramesti, Kenyo Sembodro; Hamro, Nailaufar; Yuzella, Viska; Nasution, Fitriani; Mappalilu, Arfan.
  • Alwahdy AS; Department of Neurology, Fatmawati Central General Hospital, Jl. RS. Fatmawati Raya No.4, RT.4/RW.9, Cilandak Barat, Kec. Cilandak, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta, 12430 Indonesia.
  • Margaretha IY; Department of Neurology, Fatmawati Central General Hospital, Jl. RS. Fatmawati Raya No.4, RT.4/RW.9, Cilandak Barat, Kec. Cilandak, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta, 12430 Indonesia.
  • Pramesti KS; University of UIN Syarif Hidayatullah, Tangerang, Indonesia.
  • Hamro N; University of UIN Syarif Hidayatullah, Tangerang, Indonesia.
  • Yuzella V; University of UIN Syarif Hidayatullah, Tangerang, Indonesia.
  • Nasution F; Department of Neurology, Fatmawati Central General Hospital, Jl. RS. Fatmawati Raya No.4, RT.4/RW.9, Cilandak Barat, Kec. Cilandak, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta, 12430 Indonesia.
  • Mappalilu A; Department of Neurology, Fatmawati Central General Hospital, Jl. RS. Fatmawati Raya No.4, RT.4/RW.9, Cilandak Barat, Kec. Cilandak, Kota Jakarta Selatan, Daerah Khusus Ibukota Jakarta, 12430 Indonesia.
Egypt J Neurol Psychiatr Neurosurg ; 58(1): 5, 2022.
Article in English | MEDLINE | ID: covidwho-1724612
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); however, data regarding outcomes of intravenous tissue plasminogen activator (IV TPA) administration in stroke patients with COVID-19 remains limited. CASE PRESENTATION Three AIS patients with confirmed COVID-19 treated using IV tPA. One case had excellent outcome, while the other cases showed unfavorable results. The risk-benefit ratio of IV TPA in COVID-19 remains unclear.

CONCLUSION:

In this article, we discuss the possible explanation behind these different outcomes. Although IV tPA could not cure COVID-19, we suggest that its administration should not be delayed in AIS patients with COVID-19.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Egypt J Neurol Psychiatr Neurosurg Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Prognostic study Language: English Journal: Egypt J Neurol Psychiatr Neurosurg Year: 2022 Document Type: Article